Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 29:18:991-1006.
doi: 10.2147/DDDT.S460998. eCollection 2024.

Revolutionizing Stroke Recovery: Unveiling the Promise of Stem Cell Therapy

Leonidas D Panos  1   2 , Panagiotis Bargiotas  2 , Marcel Arnold  1 , Georgios Hadjigeorgiou  2 , Georgios D Panos  3   4
Affiliations
Review

Revolutionizing Stroke Recovery: Unveiling the Promise of Stem Cell Therapy

Leonidas D Panos et al. Drug Des Devel Ther. .

Abstract

Stem cells, renowned for their unique regenerative capabilities, present significant hope in treating stroke, a major cause of disability globally. This review offers a detailed analysis of stem cell applications in stroke (ischemic and hemorrhagic) recovery. It examines therapies based on autologous (patient-derived), allogeneic (donor-derived), and Granulocyte-Colony Stimulating Factor (G-CSF) based stem cells, focusing on cell types such as Mesenchymal Stem/Stromal Cells (MSCs), Bone Marrow Mononuclear Stem Cells (BMMSCs), and Neural Stem/Progenitor Cells (NSCs). The paper compiles clinical trial data to evaluate their effectiveness and safety and addresses the ethical concerns of these innovative treatments. By explaining the mechanisms of stem cell-induced neurological repair, this review underscores stem cells' potential in revolutionizing stroke rehabilitation and suggests avenues for future research.

Keywords: allogeneic stem cells transplantation; autologous stem cells transplantation; brain hemorrhage; granulocyte-colony stimulating factor; stem cell therapy; stroke.

PubMed Disclaimer

Conflict of interest statement

Prof. Dr. Marcel Arnold reports personal fees/ grants from Astra Zeneca, Bayer, Medtronic, Novartis, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Covidien, Daiichi Sankyo, Novo Nordisk, Sanofi, Pfizer, Swiss National Science Foundation and Swiss Heart Foundation, outside the submitted work. The authors report no other conflicts of interest in this work.

References

    1. Warlow C, Gijn J. 133Stroke. In: Turner MR, Kiernan MC, editors. Landmark Papers in Neurology. Oxford University Press; 2015.
    1. Feigin VL, Brainin M, Norrving B, et al. World Stroke Organization (WSO): global Stroke Fact Sheet 2022. Int J Stroke. 2022;17(1):18–29. doi: 10.1177/17474930211065917 - DOI - PubMed
    1. Azad TD, Veeravagu A, Steinberg GK. Neurorestoration after stroke. Neurosurg Focus. 2016;40(5):E2. doi: 10.3171/2016.2.FOCUS15637 - DOI - PMC - PubMed
    1. Kondziolka D, Wechsler L, Goldstein S, et al. Transplantation of cultured human neuronal cells for patients with stroke. Neurology. 2000;55(4):565–569. doi: 10.1212/WNL.55.4.565 - DOI - PubMed
    1. Boltze J, Modo MM, Mays RW, et al. Stem Cells as an Emerging Paradigm in Stroke 4: advancing and Accelerating Preclinical Research. Stroke. 2019;50(11):3299–3306. doi: 10.1161/STROKEAHA.119.025436 - DOI - PubMed

MeSH terms

Substances